1. Home
  2. EIG vs VTYX Comparison

EIG vs VTYX Comparison

Compare EIG & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Employers Holdings Inc

EIG

Employers Holdings Inc

N/A

Current Price

$39.59

Market Cap

980.0M

Sector

Finance

ML Signal

N/A

Logo Ventyx Biosciences Inc.

VTYX

Ventyx Biosciences Inc.

HOLD

Current Price

$13.99

Market Cap

990.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EIG
VTYX
Founded
2000
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
980.0M
990.9M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
EIG
VTYX
Price
$39.59
$13.99
Analyst Decision
Hold
Analyst Count
0
7
Target Price
N/A
$13.50
AVG Volume (30 Days)
264.8K
3.6M
Earning Date
05-22-2026
01-01-0001
Dividend Yield
3.23%
N/A
EPS Growth
N/A
40.30
EPS
0.46
N/A
Revenue
$858,700,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.76
N/A
P/E Ratio
$86.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.73
$0.90
52 Week High
$51.23
$15.34

Technical Indicators

Market Signals
Indicator
EIG
VTYX
Relative Strength Index (RSI) 36.48 72.58
Support Level $38.29 $13.89
Resistance Level $43.30 $14.07
Average True Range (ATR) 1.59 0.03
MACD -0.13 -0.11
Stochastic Oscillator 31.51 88.89

Price Performance

Historical Comparison
EIG
VTYX

About EIG Employers Holdings Inc

Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.

About VTYX Ventyx Biosciences Inc.

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Share on Social Networks: